Patents Represented by Attorney Wilson Sonsini Goodrich & Rosati PC
-
Patent number: 8323670Abstract: Provided are topical compositions comprising opioid antagonists, such as naltrexone or naloxone, or their pharmaceutically acceptable salts, and methods for treating skin conditions, such as those caused by human papillomavirus, therewith.Type: GrantFiled: September 28, 2010Date of Patent: December 4, 2012Assignee: Ak Kimya Ithalat-Ihracat Ve Sanayii A.S.Inventors: Ibrahim Mustafa Iskender Pisak, Semra Bingol, Mehmet Levent Selamoglu, Nevhiz Pak
-
Patent number: 7996170Abstract: A method and apparatus that enables a user to sort data from one or more sample lots, which may be obtained via a network, such as the Internet, into a composite parameter structure. The composite parameter structure is a function of one or more parameters corresponding to one or more characteristics associated with one or more sample lots. The composite parameter structure representation may be printed, stored, or transmitted to another location. A server device that is coupled and working in conjunction with a client device may implement the present invention.Type: GrantFiled: May 14, 2009Date of Patent: August 9, 2011Assignee: Par Pharmaceutical, Inc.Inventors: Robert Ruemer, Narayan Ragunathan, Robert A. Femia
-
Patent number: 7957913Abstract: The present invention relates to genetic analysis and evaluation utilizing copy-number variants or polymorphisms. The methods utilize array comparative genomic hybridization and PCR assays to identify the significance of copy number variations in a subject or subject group.Type: GrantFiled: February 17, 2010Date of Patent: June 7, 2011Assignee: Population Diagnostics, Inc.Inventors: James Chinitz, Eli Hatchwell
-
Patent number: 7939258Abstract: The invention provides methods for amplification of polynucleotide sequences using primers containing single-stranded RNA. The methods employ use of an enzyme capable of cleaving single-stranded RNA, such as RNase I, to degrade a first RNA-containing primer prior to addition of a second RNA-containing primer. The invention also provides compositions and kits for practicing the amplification methods, as well as methods which use the amplification products.Type: GrantFiled: September 7, 2006Date of Patent: May 10, 2011Assignee: Nugen Technologies, Inc.Inventors: Nurith Kurn, Shenglong Wang
-
Patent number: 7906159Abstract: Compositions, kits and methods are provided for enhancing vital energy and athletic performance, improving or restoring blood circulation, promoting mental acuity, reducing fatigue, and improving aerobic performance. In one embodiment, the composition comprises the herbal extracts of Rhodiola crenulata (root) and Ginkgo biloba (leaf). The composition can be used as a pharmaceutical or nutraceutical to promote mental concentration, and to promote aerobic and anaerobic performance by enhancing strength, endurance, muscle tissue oxygenation, and optimal oxygen consumption.Type: GrantFiled: April 17, 2009Date of Patent: March 15, 2011Inventors: Wen Hsien Chou, Vivien Chou
-
Patent number: 7892534Abstract: Existence of human trophoblast stem (hTS) cells has been suspected but unproved. The isolation of hTS cells is reported in the early stage of chorionic villi by expressions of FGF4, FGFR-2, Oct4, Thy-1, and stage-specific embryonic antigens distributed in different compartments of the cell. hTS cells are able to derive into specific cell phenotypes of the three primitive embryonic layers, produce chimeric reactions in mice, and retain a normal karyotype and telomere length. In hTS cells, Oct4 and fgfr-2 expressions can be knockdown by bFGF. These facts suggest that differentiation of the hTS cells play an important role in implantation and placentation. hTS cells could be apply to human cell differentiation and for gene and cell-based therapies.Type: GrantFiled: March 16, 2009Date of Patent: February 22, 2011Inventors: Jau-Nan Lee, Tony Tung-Ying Lee, Yuta Lee
-
Patent number: 7893044Abstract: A method of treating adenosine depletion in a subject in need of such treatment is disclosed. The method comprises administering to the subject folinic acid or a pharmaceutically acceptable salt thereof in an amount effective to treat adenosine depletion. A method of treating asthma in a subject in need of such treatment is also disclosed. The method comprises administering to the subject dehydroepiandrosterone, analogs thereof, or pharmaceutically acceptable salts thereof in an amount effective to treat asthma.Type: GrantFiled: August 20, 2004Date of Patent: February 22, 2011Assignee: EpiGenesis Pharmaceutical, Inc.Inventor: Jonathan W. Nyce
-
Patent number: 7879363Abstract: The method for increasing lactose tolerance in subjects exhibiting lactose intolerance symptoms implements a protocol where the subjects ingest a gradually increasing amount of lactose containing product over a six week period. At various points during the six week period the subject ingests the lactose containing product once a day and then twice a day. The lactose containing product can be in liquid form, such as for example, milk, and is preferably in a powder form which is taken either by ingesting capsules having the lactose powder or in a granular form mixed with water or other non-lactose containing liquid. At the end of the six week period, the subject's tolerance for lactose containing products is substantially increased, with the potential of eliminating the subject's lactose intolerant behavior indefinitely.Type: GrantFiled: January 11, 2008Date of Patent: February 1, 2011Assignee: Ritter Pharmaceuticals, Inc.Inventor: Andrew J. Ritter
-
Patent number: 7872050Abstract: A composition and method for treatment of cancer. The composition for treating a skin disorder, comprising: a Nitrogen Mustard or an HX salt of the Nitrogen Mustard, wherein the Nitrogen Mustard or the HX salt of the Nitrogen Mustard is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol, wherein the non-aqueous vehicle or carrier that does not include petrolatum or ethanol does not include petrolatum or ethanol. The method comprises topically applying the composition of a Nitrogen Mustard or a HX salt of the Nitrogen Mustard to the affected skin, wherein the Nitrogen Mustard or the HX salt of the Nitrogen Mustard is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol, wherein the non-aqueous vehicle or carrier does not include petrolatum or ethanol.Type: GrantFiled: March 7, 2006Date of Patent: January 18, 2011Assignee: Yaupon Therapeutics Inc.Inventors: Robert Alonso, Peter A. Crooks, Mark A. Pimley
-
Patent number: 7873589Abstract: A system for developing and implementing empirically derived algorithms to generate decision rules to predict invalidity of subject reported data and fraud with research protocols in surveys allows for the identification of complex patterns of variables that detect or predict subject invalidity of subject reported data and fraud with the research protocol in the survey. The present invention may also be used to monitor invalidity of subject reported data within a research protocol to determine preferred actions to be performed. Optionally, the invention may provide a spectrum of invalidity, from minor invalidity needing only corrective feedback, to significant invalidity requiring subject removal from the survey. The algorithms and decision rules can also be domain-specific, such as detecting invalidity or fraud among subjects in a workplace satisfaction survey, or demographically specific, such as taking into account gender or age.Type: GrantFiled: August 24, 2007Date of Patent: January 18, 2011Assignee: Invivodata, Inc.Inventors: Saul Shiffman, Douglas R. Engfer, Jean Paty
-
Patent number: 7838564Abstract: A composition and method for treatment of cancer. The composition for treating a skin disorder, comprising: a Nitrogen Mustard or an HX salt of the Nitrogen Mustard, wherein the Nitrogen Mustard or the HX salt of the Nitrogen Mustard is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol, wherein the non-aqueous vehicle or carrier that does not include petrolatum or ethanol does not include petrolatum or ethanol. The method comprises topically applying the composition of a Nitrogen Mustard or a HX salt of the Nitrogen Mustard to the affected skin, wherein the Nitrogen Mustard or the HX salt of the Nitrogen Mustard is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol, wherein the non-aqueous vehicle or carrier does not include petrolatum or ethanol.Type: GrantFiled: August 27, 2009Date of Patent: November 23, 2010Assignee: Yaupon Therapeutics Inc.Inventors: Robert Alonso, Peter A. Crooks, Mark A. Pimley, Abeer M. Al-Ghananeem
-
Patent number: 7834055Abstract: An ascorbic acid-based composition and related method for the treatment of aging, photo-damaged or inflamed skin is disclosed. The composition includes water and ascorbic acid, at least a portion of which has generally been pretreated by being dissolved under relatively high temperature and concentration conditions. The composition typically includes at least about 5.0% (w/v) ascorbic acid formulated to have a pH above 3.5. 10 to 50% of the ascorbic acid is pretreated ascorbic acid. The composition may also include a non-toxic zinc salt, a tyrosine compound, and/or pharmaceutically acceptable carrier. The composition may include an anti-inflammatory compound, such as aminosugar and/or sulfur-containing anti-inflammatory compound. Embodiments containing an aminosugar such as glucosamine are further useful for treating rosacea and other inflammatory skin ailments. The composition may be administered in a variety of forms suitable for topical application on skin.Type: GrantFiled: January 16, 2008Date of Patent: November 16, 2010Assignee: Bioderm, Inc.Inventor: Lorraine Faxon Meisner
-
Patent number: 7816402Abstract: An ascorbic acid-based composition and related method for the treatment of aging, photo-damaged or inflamed skin is disclosed. The composition includes water and ascorbic acid, at least a portion of which has generally been pretreated by being dissolved under relatively high temperature and concentration conditions. The composition typically includes at least about 5.0% (w/v) ascorbic acid formulated to have a pH above 3.5. 10 to 50% of the ascorbic acid is pretreated ascorbic acid. The composition may also include a non-toxic zinc salt, a tyrosine compound, and/or pharmaceutically acceptable carrier. The composition may include an anti-inflammatory compound, such as aminosugar and/or sulfur-containing anti-inflammatory compound. Embodiments containing an aminosugar such as glucosamine are further useful for treating rosacea and other inflammatory skin ailments. The composition may be administered in a variety of forms suitable for topical application on skin.Type: GrantFiled: November 29, 2001Date of Patent: October 19, 2010Assignee: Bioderm, Inc.Inventor: Lorraine Faxon Meisner
-
Patent number: 7759472Abstract: The invention features methods for treating a patient diagnosed with, or at risk of developing, a neovascular disorder by administering a PDGF antagonist and a VEGF antagonist to the patient. The invention also features a pharmaceutical composition containing a PDGF antagonist and a VEGF antagonist for the treatment or prevention of a neovascular disorder.Type: GrantFiled: August 26, 2004Date of Patent: July 20, 2010Assignee: Ophthotech CorporationInventors: David Shima, Perry Calias, Anthony P. Adamis
-
Patent number: 7745435Abstract: The present invention relates to novel Triheterocyclic Compounds, compositions comprising a Triheterocyclic Compound, and methods useful for treating or preventing cancer or a neoplastic disorder comprising administering a Triheterocyclic Compound. The compounds, compositions, and methods of the invention are also useful for inhibiting the growth of a cancer cell or neoplastic cell, treating or preventing a viral infection, or inhibiting the replication and/or infectivity of a virus.Type: GrantFiled: July 18, 2008Date of Patent: June 29, 2010Assignee: Gemix X Pharmaceuticals Canada Inc.Inventors: Giorgio Attardo, Jean-Francois Lavallee, Elise Rioux, Sasmita Tripathy, Terrence W. Doyle
-
Patent number: 7723059Abstract: A method to facilitate recovery troponin I and/or troponin T from a sample comprising addition of troponin C to the sample or to a surface from which the troponin I and/or troponin T are recovered.Type: GrantFiled: February 9, 2007Date of Patent: May 25, 2010Assignee: Biosite IncorporatedInventors: Kenneth F. Buechler, Paul H. McPherson
-
Patent number: 7709477Abstract: The present invention relates to novel Triheterocyclic Compounds, compositions comprising a Triheterocyclic Compound, and methods useful for treating or preventing cancer or a neoplastic disorder comprising administering a Triheterocyclic Compound. The compounds, compositions, and methods of the invention are also useful for inhibiting the growth of a cancer cell or neoplastic cell, treating or preventing a viral infection, or inhibiting the replication and/or infectivity of a virus.Type: GrantFiled: July 18, 2008Date of Patent: May 4, 2010Assignee: Gemin X Pharmaceuticals Canada Inc.Inventors: Giorgio Attardo, Jean-Francois Lavallee, Elise Rioux, Sasmita Tripathy, Terrence W. Doyle
-
Patent number: 7705118Abstract: The present invention relates to a method for preparing a peptide having a stable, internally constrained alpha-helical, beta-sheet/beta-turn, 310-helical, or pi-helical region and a method of stabilizing an alpha-helical, beta-sheet/beta-turn, 310-helical, or pi-helical region within a peptide structure. The resulting peptides and methods of using them are also disclosed.Type: GrantFiled: February 26, 2007Date of Patent: April 27, 2010Assignee: New York UniversityInventors: Paramjit Arora, Ross Chapman
-
Patent number: 7702468Abstract: The present invention relates to genetic analysis and evaluation utilizing copy-number variants or polymorphisms. The methods utilize array comparative genomic hybridization and PCR assays to identify the significance of copy number variations in a subject or subject group.Type: GrantFiled: May 31, 2006Date of Patent: April 20, 2010Assignee: Population Diagnostics, Inc.Inventors: James Chinitz, Eli Hatchwell
-
Patent number: D655642Type: GrantFiled: July 19, 2011Date of Patent: March 13, 2012Inventor: Scott Francis Mogren